{"success":true,"data":{"pressRelease":{"id":"131065","rtpr_id":"nGNX2252LK","ticker":"KLRS","exchange":"NASDAQ","all_tickers":["KLRS"],"title":"Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference","author":"Globe Newswire","published_at":"2026-08-31T12:00:00.292Z","article_body":"BERKELEY HEIGHTS, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kalaris\nTherapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage\nbiopharmaceutical company dedicated to the development and commercialization\nof treatments for prevalent retinal diseases, today announced that management\nwill participate in a Fireside Chat at the upcoming Morgan Stanley 24th Annual\nGlobal Healthcare Conference. Kalaris is currently developing TH103, a\ndual-action anti-VEGF therapeutic, in a Phase 1b/2 multiple ascending dose\nstudy for neovascular Age-related Macular Degeneration (nAMD).\n\nDetails:\n* Type: Fireside chat\n* Speakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief\nMedical Officer\n* Date: Tuesday, September 15, 2026\n* Time: 4:05 – 4:40pm EDT\n* Location: New York, NY\nKalaris management will be available for one-on-one meetings during the\nconference. Interested parties should contact their conference representative\nto arrange a meeting.\n\nAbout TH103\nTH103 is an investigational dual-targeting biologic with the potential to be\nbest-in class for neovascular and exudative retinal diseases. TH103 was\nengineered by VEGF scientific discoverer Dr. Napoleone Ferrara to achieve\nextended intraocular retention with enhanced VEGF inhibition through optimized\nbinding to VEGF receptor 1 ligands and concurrent heparan sulfate proteoglycan\n(HSPG) anchoring. It is a fully humanized, recombinant fusion protein designed\nfor intravitreal delivery, with potential applications as a treatment for\nexudative and/or neovascular retinal diseases, such as neovascular Age-related\nMacular Degeneration (nAMD), diabetic eye disease and retinal vein occlusion.\nTH103 is currently being investigated in a Phase 1b/2 clinical trial in\npatients with nAMD.\n\nAbout Kalaris\nKalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated\nto the development and commercialization of treatments for prevalent retinal\ndiseases. Founded by renowned scientist Dr. Napoleone Ferrara, whose\npioneering research led to the development of anti-VEGF therapy, the company\nis committed to advancing novel therapeutic approaches for patients with\nsight-threatening retinal conditions with major unmet medical needs.\n\nFor more information, visit www.kalaristx.com.\n\nKalaris Therapeutics Investor Contact:\nCorey Davis, Ph.D.\nLifeSci Advisors, LLC\n+1 212 915 2577\ncdavis@lifesciadvisors.com \nir@kalaristx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f8fc91d0-2885-4bb6-ba21-c1c5c57a666b)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2252LK","title":"Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference","author":"Globe Newswire","ticker":"KLRS","created":"2026-08-31T12:00:00.292Z","tickers":["KLRS"],"exchange":"NASDAQ","article_body":"BERKELEY HEIGHTS, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kalaris\nTherapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage\nbiopharmaceutical company dedicated to the development and commercialization\nof treatments for prevalent retinal diseases, today announced that management\nwill participate in a Fireside Chat at the upcoming Morgan Stanley 24th Annual\nGlobal Healthcare Conference. Kalaris is currently developing TH103, a\ndual-action anti-VEGF therapeutic, in a Phase 1b/2 multiple ascending dose\nstudy for neovascular Age-related Macular Degeneration (nAMD).\n\nDetails:\n* Type: Fireside chat\n* Speakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief\nMedical Officer\n* Date: Tuesday, September 15, 2026\n* Time: 4:05 – 4:40pm EDT\n* Location: New York, NY\nKalaris management will be available for one-on-one meetings during the\nconference. Interested parties should contact their conference representative\nto arrange a meeting.\n\nAbout TH103\nTH103 is an investigational dual-targeting biologic with the potential to be\nbest-in class for neovascular and exudative retinal diseases. TH103 was\nengineered by VEGF scientific discoverer Dr. Napoleone Ferrara to achieve\nextended intraocular retention with enhanced VEGF inhibition through optimized\nbinding to VEGF receptor 1 ligands and concurrent heparan sulfate proteoglycan\n(HSPG) anchoring. It is a fully humanized, recombinant fusion protein designed\nfor intravitreal delivery, with potential applications as a treatment for\nexudative and/or neovascular retinal diseases, such as neovascular Age-related\nMacular Degeneration (nAMD), diabetic eye disease and retinal vein occlusion.\nTH103 is currently being investigated in a Phase 1b/2 clinical trial in\npatients with nAMD.\n\nAbout Kalaris\nKalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated\nto the development and commercialization of treatments for prevalent retinal\ndiseases. Founded by renowned scientist Dr. Napoleone Ferrara, whose\npioneering research led to the development of anti-VEGF therapy, the company\nis committed to advancing novel therapeutic approaches for patients with\nsight-threatening retinal conditions with major unmet medical needs.\n\nFor more information, visit www.kalaristx.com.\n\nKalaris Therapeutics Investor Contact:\nCorey Davis, Ph.D.\nLifeSci Advisors, LLC\n+1 212 915 2577\ncdavis@lifesciadvisors.com \nir@kalaristx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f8fc91d0-2885-4bb6-ba21-c1c5c57a666b)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-31T12:00:00.454491106Z","server_sent_at_ms":1788177600454},"received_at":"2026-08-31T12:00:00.558Z","source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353242/0/en/kalaris-to-present-at-morgan-stanley-24th-annual-global-healthcare-conference.html"},"analysis":{"id":"119972","press_release_id":"131065","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Kalaris Therapeutics announced that management will participate in a Fireside Chat at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference.\n\nCEO Andrew Oxtoby and CMO Matthew Feinsod are scheduled to speak on Tuesday, September 15, 2026, from 4:05 to 4:40pm EDT.\n\nThe company is developing TH103, a dual-action anti-VEGF therapeutic, currently in a Phase 1b/2 study for neovascular Age-related Macular Degeneration.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference attendance visibility update."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[{"name":"Andrew Oxtoby","role":"Chief Executive Officer"},{"name":"Matthew Feinsod","role":"Chief Medical Officer"},{"name":"Dr. Napoleone Ferrara","role":"Founder/Scientific discoverer"}],"products":["TH103"],"companies":[{"name":"Kalaris Therapeutics, Inc.","ticker":"KLRS"},{"name":"Morgan Stanley","relationship":"conference host"},{"name":"LifeSci Advisors, LLC","relationship":"investor relations"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine corporate announcement of management participation in a conference fireside chat. No new clinical, financial, or operational data were disclosed."},"tickerRelevance":{"others":[],"primary":"KLRS"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"conference_participation"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Kalaris Therapeutics announced that management will participate in a Fireside Chat at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference.\n\nCEO Andrew Oxtoby and CMO Matthew Feinsod are scheduled to speak on Tuesday, September 15, 2026, from 4:05 to 4:40pm EDT.\n\nThe company is developing TH103, a dual-action anti-VEGF therapeutic, currently in a Phase 1b/2 study for neovascular Age-related Macular Degeneration.","key_figures":null,"named_entities":{"people":[{"name":"Andrew Oxtoby","role":"Chief Executive Officer"},{"name":"Matthew Feinsod","role":"Chief Medical Officer"},{"name":"Dr. Napoleone Ferrara","role":"Founder/Scientific discoverer"}],"products":["TH103"],"companies":[{"name":"Kalaris Therapeutics, Inc.","ticker":"KLRS"},{"name":"Morgan Stanley","relationship":"conference host"},{"name":"LifeSci Advisors, LLC","relationship":"investor relations"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-31T12:13:56.964Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"small-cap","eventGravity":"conference_participation"}},"durationMs":86380,"modelName":"glm-4.7"}}